Acute effects of a session of electroconvulsive therapy on brain-derived neurotrophic factor plasma levels

Span J Psychiatry Ment Health. 2023 Jul-Sep;16(3):137-142. doi: 10.1016/j.rpsm.2020.05.011. Epub 2020 Jul 14.

Abstract

Brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) are neurotrophins that play critical roles in brain neuronal function. Previous studies have established the association between BDNF and NGF signaling and severe mental disorders, but changes in BDNF plasma levels and electroconvulsive therapy (ECT) response are controversial. The aim of his study was to explore the acute effects of a single session of ECT on these neurotrophins signaling. Plasma levels of BDNF and NGF and their tyrosine kinase-type receptors expression in peripheral blood mononuclear cells (PBMCs) were determined before and two hours after a single ECT session in 30 subjects with a severe mental disorder. Two hours after an ECT session we found a statistically significant decrease of BDNF plasma levels (p=0.007). We did not find significant acute effects on NGF plasma levels or receptors expression in PBMCs. We found a significant inverse correlation between the time of convulsion and BDNF plasma levels decrease (r=-0.041, p=0.024). We have identified a decrease in BDNF plasma levels after 2h of a single ECT session. These results indicate the interest for future research in the role of neurotrophins in the response and safety of ECT.

Keywords: BDNF; Biomarkers; Brain-derived neurotrophic factor; ECT; Electroconvulsive therapy.

MeSH terms

  • Brain-Derived Neurotrophic Factor* / blood
  • Electroconvulsive Therapy* / methods
  • Humans
  • Leukocytes, Mononuclear
  • Nerve Growth Factor / blood
  • Receptor Protein-Tyrosine Kinases

Substances

  • Brain-Derived Neurotrophic Factor
  • Nerve Growth Factor
  • Receptor Protein-Tyrosine Kinases